These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 14762605)

  • 41. Basic parameters of articulatory movements and acoustics in individuals with Parkinson's disease.
    Walsh B; Smith A
    Mov Disord; 2012 Jun; 27(7):843-50. PubMed ID: 22729986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease.
    Skodda S; Visser W; Schlegel U
    J Neural Transm (Vienna); 2010 Feb; 117(2):197-205. PubMed ID: 20012657
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Language production in Parkinson's disease: acoustic and linguistic considerations.
    Illes J; Metter EJ; Hanson WR; Iritani S
    Brain Lang; 1988 Jan; 33(1):146-60. PubMed ID: 3342316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A study of voice profiles and acoustic signs in patients with Parkinson's disease in North India.
    Lazarus JP; Vibha D; Handa KK; Singh S; Goyal V; Srivastava T; Aggarwal V; Behari M
    J Clin Neurosci; 2012 Aug; 19(8):1125-9. PubMed ID: 22721893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment of vocal symptoms in Parkinson's disease: the Lee Silverman method].
    Dias AE; Limongi JC
    Arq Neuropsiquiatr; 2003 Mar; 61(1):61-6. PubMed ID: 12715021
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acoustic and perceptual speech characteristics of native Mandarin speakers with Parkinson's disease.
    Hsu SC; Jiao Y; McAuliffe MJ; Berisha V; Wu RM; Levy ES
    J Acoust Soc Am; 2017 Mar; 141(3):EL293. PubMed ID: 28372040
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acoustic voice assessment in Parkinson's disease patients submitted to posteroventral pallidotomy.
    Mourão LF; Aguiar PM; Ferraz FA; Behlau MS; Ferraz HB
    Arq Neuropsiquiatr; 2005 Mar; 63(1):20-5. PubMed ID: 15830059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intonation and speech rate in Parkinson's disease: general and dynamic aspects and responsiveness to levodopa admission.
    Skodda S; Grönheit W; Schlegel U
    J Voice; 2011 Jul; 25(4):e199-205. PubMed ID: 21051196
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Voice Quality and Orofacial Strength as Outcome of Levodopa Effectiveness in Patients with Early Idiopathic Parkinson Disease: A Preliminary Report.
    Lechien JR; Blecic S; Ghosez Y; Huet K; Harmegnies B; Saussez S
    J Voice; 2019 Sep; 33(5):716-720. PubMed ID: 29724466
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease.
    Isobe C; Abe T; Kikuchi T; Murata T; Sato C; Terayama Y
    Eur J Neurol; 2006 Apr; 13(4):346-50. PubMed ID: 16643311
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gender-related patterns of dysprosody in Parkinson disease and correlation between speech variables and motor symptoms.
    Skodda S; Visser W; Schlegel U
    J Voice; 2011 Jan; 25(1):76-82. PubMed ID: 20381998
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emotional speech in Parkinson's disease.
    Möbes J; Joppich G; Stiebritz F; Dengler R; Schröder C
    Mov Disord; 2008 Apr; 23(6):824-9. PubMed ID: 18307245
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems.
    Plowman-Prine EK; Okun MS; Sapienza CM; Shrivastav R; Fernandez HH; Foote KD; Ellis C; Rodriguez AD; Burkhead LM; Rosenbek JC
    NeuroRehabilitation; 2009; 24(2):131-44. PubMed ID: 19339752
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Task-based profile of vocal intensity decline in Parkinson's disease.
    Rosen KM; Kent RD; Duffy JR
    Folia Phoniatr Logop; 2005; 57(1):28-37. PubMed ID: 15655339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Levodopa: effect on cell death and the natural history of Parkinson's disease.
    Olanow CW
    Mov Disord; 2015 Jan; 30(1):37-44. PubMed ID: 25502620
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reading fluency in Spanish patients with Parkinson's disease: A reading prosody examination.
    Pérez-Sánchez MDC; González-Nosti M; Cuetos F; Álvarez-Cañizo M
    Int J Lang Commun Disord; 2023 Mar; 58(2):357-375. PubMed ID: 36269041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Speech prosody impairment predicts cognitive decline in Parkinson's disease.
    Rektorova I; Mekyska J; Janousova E; Kostalova M; Eliasova I; Mrackova M; Berankova D; Necasova T; Smekal Z; Marecek R
    Parkinsonism Relat Disord; 2016 Aug; 29():90-5. PubMed ID: 27237105
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vocal acoustic characteristics of patients with Parkinson's disease.
    Tanaka Y; Nishio M; Niimi S
    Folia Phoniatr Logop; 2011; 63(5):223-30. PubMed ID: 21212679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acoustic voice analysis in patients with Parkinson's disease treated with dopaminergic drugs.
    Gamboa J; Jiménez-Jiménez FJ; Nieto A; Montojo J; Ortí-Pareja M; Molina JA; García-Albea E; Cobeta I
    J Voice; 1997 Sep; 11(3):314-20. PubMed ID: 9297676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.